Group P (n = 45) | Group S (n = 45) | p value | |
---|---|---|---|
Gender (male/female) | 20/25 | 21/24 | 0.832α |
Age – years (mean ± SD) | 43.2 ± 15.1 | 40.7 ± 11.9 | 0.862β |
Body weight – kg (mean ± SD) | 56.7 ± 7.9 | 53.3 ± 9.4 | 0.440β |
Height – m (mean ± SD) | 161.6 ± 6.9 | 161.4 ± 6.8 | 0.951β |
MGFA classification – no. (%) | |||
I | 15 (33) | 13 (28) | 0.109α |
IIa | 27 (60) | 22 (49) | |
IIb | 3 (7) | 10 (22) | |
Disease duration-months (mean, range) | 34.3 (1–96) | 28.8 (1–108) | 0.549γ |
Thyroma (yes/no) | 41/4 | 37/8 | 0.353δ |
Pre-operative treatment | |||
Pyridostigmine – no. dosage-mg.day−1 (mean, range) | 45 263 (60–600) | 45 224 (60–540) | 0.226β |
Prednisone – no | 5 | 10 | 0.157α |
Plasmapheresis – no | 6 | 7 | 0.764α |